A second chance for success with BRAF and MEK inhibitors in melanoma
- PMID: 28268065
- DOI: 10.1016/S1470-2045(17)30151-1
A second chance for success with BRAF and MEK inhibitors in melanoma
Comment on
-
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.Lancet Oncol. 2017 Apr;18(4):464-472. doi: 10.1016/S1470-2045(17)30171-7. Epub 2017 Mar 4. Lancet Oncol. 2017. PMID: 28268064
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
